

Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company’s first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.
We will give women everywhere control of their sexual and reproductive health.
2 Angestellte bei Evofem Biosciences haben Evofem Biosciences über verschiedene Kulturdimensionen hinweg rezensiert, wobei sie Ihre Meinungen zu Themen wie die Bewertung von Führungskräften bis hin zum Arbeitstempo äußern. Die neuste Rezension war vor Monate
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.









Lack of leadership. Very inexperienced.

Sagen Sie Evofem Biosciences, dass Sie interessiert sind dort zu arbeiten, ihre persönlichen Informationen bleiben dabei anonym. Comparably gibt Evofem Biosciences die Gelegenheit, Sie anzustellen. Wenn es eine passende Stelle gibt, matchen wir diese.
| 50% | Promoters |
|---|---|
| 0% | Passives |
| 50% | Detractors |





Senden Sie ihnen eine Einladung, um die Unternehmenskultur zu bewerten.